Aspire Pharma completed the acquisition of Cenote Pharma.

Aspire Pharma, a manufacturer of generic and specialty pharmaceutical products, completed the acquisition of Cenote Pharma, a category specialist in carnitine deficiencies. Financial terms were not disclosed. “We are excited to bring an additional therapy area into our portfolio at Aspire. This acquisition underscores our commitment to advance the science and treatment options for vulnerable patient groups, with Aspire’s capabilities, we will also push to gain regulatory approval in multiple global markets in the near future,” Richard Condon, Aspire Chief Executive Officer.